|
Dec 7
|
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
|
|
Dec 7
|
REFILE-UPDATE 1-Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline
|
|
Dec 7
|
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
|
|
Dec 6
|
Merck KGaA Plunges as Multiple Sclerosis Drug Fails in Trial
|
|
Dec 5
|
UPDATE 2-Merck KGaA suffers major blow as MS drug fails in late-stage trials
|
|
Nov 30
|
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
|
|
Nov 30
|
2 Biotech Stocks You Can Buy and Hold for the Next Decade
|
|
Nov 28
|
UPDATE 2-White House urges RSV immunization makers to meet demand
|
|
Nov 27
|
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
|
|
Nov 27
|
How the high-stakes world of Formula 1 racing inspired Sanofi CEO Paul Hudson to deliver more medicines
|
|
Nov 27
|
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
|
|
Nov 27
|
Regeneron, Sanofi to seek new Dupixent approval in US after COPD success
|
|
Nov 27
|
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
|
|
Nov 27
|
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
|
|
Nov 26
|
12 Best Diabetes Stocks To Buy Now
|
|
Nov 25
|
3 Top Dividend Champions With Market-Beating Yields
|
|
Nov 15
|
Biotech raises funds to find cancer treatments using transgenic mice
|
|
Nov 15
|
MeiraGTx Holdings PLC Reports Q3 2023 Financial Results and Operational Progress
|
|
Nov 10
|
AstraZeneca prioritizes US for RSV drug amid surge in cases
|
|
Nov 10
|
Optum Rx moves 8 insulins to preferred formulary status as pressure mounts on PBMs
|